Gulhan Demir

Gulhan Demir

Auto-generated profile, based on publicly available information

Gulhan Demir

KOCAELİ ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ, TIBBİ GENETİK VE MOLEKÜLER BİYOLOJİ ANABİLİM DALI

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Biotechnology
Verified
Journal Article
Closed access
HSHakan Savli
Hakan Savli
NSNilüfer Sertdemir
Nilüfer Sertdemir
DADuygu Aydin
Duygu Aydin
BDBilge Dursun
Bilge Dursun
OKOmer Kurtas
Omer Kurtas
NCNaci Cine
Naci Cine

3 October 2022 in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
SKSeda Eren Keski̇n
Seda Eren Keski̇n
EGEda Güzdolu
Eda Güzdolu
NSNilüfer Sertdemi̇r
Nilüfer Sertdemi̇r
GDGülhan Demi̇r
Gülhan Demi̇r
DADeniz Sünnetçi Akkoyunlu
Deniz Sünnetçi Akkoyunlu
HSHakan Savli
Hakan Savli
Objective: RAS genes are members of the RAS/Mitogen activated protein kinase pathway which is induced by Epidermal Growth Factor Receptor (EGFR). Mutations in genes in this pathway trigger cancer development. In colorectal cancer, mutations in RAS genes cause resistance to EGRF- targeted therapy. In the treatment of metastatic colorectal cancer, EGFR’s monoclonal antibodies are widely used as chemotherapeutic agents. Kirsten-RAS mutations are found in 30-50% and N-RAS mutations are found in 2-3% of colorectal cancer. In this study, we aimed to analyze Kirsten-RAS /N-RAS mutations in patients with metastatic colorectal cancer. Methods: One hundred of metastatic colorectal cancer patients resistant to EGFR- targeted therapy were scanned for the Kirsten-RAS mutations status (exon 2,3,4) and N-RAS mutation status (Exon 2,3,4) by Real-Time PCR (Polymerase Chain Reaction) method. Results: As a result of this study, Kirsten-RAS mutation was found 48% and N-RAS mutation was 1.92%. The most common Kirsten-RAS mutations were in codon 12. The distribution of codon 12 mutations were obtained as G12V (25%), G12D (23%), G12C (14.5%). Conclusion: In our study, the frequencies of Kirsten-RAS and N-RAS mutations were compitable with similar reports. Our results have supported that testing RAS genes mutations have a vital role in identifying patients who benefit from Epidermal Growth Factor Receptor- targeted therapy.